-
Hellenic Journal of Cardiology : HJC =... 2021
Topics: Humans; Mitral Valve; Mitral Valve Insufficiency; Mitral Valve Stenosis
PubMed: 33771729
DOI: 10.1016/j.hjc.2021.03.002 -
Heart (British Cardiac Society) May 2020
Topics: Atrial Fibrillation; Humans; Incidence; Mitral Valve Stenosis; Republic of Korea; Treatment Outcome
PubMed: 32029526
DOI: 10.1136/heartjnl-2019-316282 -
Journal of the American College of... Sep 2018Rheumatic heart disease (RHD) is a preventable heart condition that remains endemic among vulnerable groups in many countries. After a period of relative neglect, there... (Review)
Review
Rheumatic heart disease (RHD) is a preventable heart condition that remains endemic among vulnerable groups in many countries. After a period of relative neglect, there has been a resurging interest in RHD worldwide over the past decade. In this Scientific Expert Panel, the authors summarize recent advances in the science of RHD and sketch out priorities for current action and future research. Key questions for laboratory research into disease pathogenesis and epidemiological research on the burden of disease are identified. The authors present a variety of pressing clinical research questions on optimal RHD prevention and advanced care. In addition, they propose a policy and implementation research agenda that can help translate current evidence into tangible action. The authors maintain that, despite knowledge gaps, there is sufficient evidence for national and global action on RHD, and they argue that RHD is a model for strengthening health systems to address other cardiovascular diseases in limited-resource countries.
Topics: Anti-Bacterial Agents; Atrial Fibrillation; Chemoprevention; Echocardiography; Endocarditis, Bacterial; Female; Global Health; Heart Failure; Humans; Mitral Valve Stenosis; Pharyngitis; Pregnancy; Pregnancy, High-Risk; Prenatal Care; Primary Prevention; Rheumatic Heart Disease; Secondary Prevention; Streptococcal Infections; Streptococcus pyogenes; Stroke
PubMed: 30213333
DOI: 10.1016/j.jacc.2018.06.063 -
BMJ Case Reports May 2017
Topics: Adult; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Hypertension, Pulmonary; Mitral Valve; Mitral Valve Stenosis; Phonocardiography
PubMed: 28512104
DOI: 10.1136/bcr-2017-220120 -
Journal of the American College of... Jun 2020
Topics: Aging; Calcinosis; Constriction, Pathologic; Humans; Mitral Valve; Mitral Valve Stenosis
PubMed: 32553259
DOI: 10.1016/j.jacc.2020.04.056 -
Cardiology 2018
Topics: Catheterization; Heart Atria; Heart Valve Prosthesis Implantation; Humans; Mitral Valve Stenosis; Rheumatic Heart Disease
PubMed: 29772580
DOI: 10.1159/000487664 -
Methodist DeBakey Cardiovascular Journal 2017Transcatheter mitral valve replacement (TMVR) is a novel approach for treatment of severe mitral regurgitation. A number of TMVR devices are currently undergoing... (Review)
Review
Transcatheter mitral valve replacement (TMVR) is a novel approach for treatment of severe mitral regurgitation. A number of TMVR devices are currently undergoing feasibility trials using both transseptal and transapical routes for device delivery. Overall experience worldwide is limited to fewer than 200 cases. At present, the 30-day mortality exceeds 30% and is attributable to both patient- and device-related factors. TMVR has been successfully used to treat patients with degenerative mitral stenosis (DMS) as well as failed mitral bioprosthesis and mitral repair using transcatheter mitral valve-in-valve (TMViV)/valve-in-ring (ViR) repair. These patients are currently treated with devices designed for transcatheter aortic valve replacement. Multicenter registries have been initiated to collect outcomes data on patients currently undergoing TMViV/ViR and TMVR for DMS and have confirmed the feasibility of TMVR in these patients. However, the high periprocedural and 30-day event rates underscore the need for further improvements in device design and multicenter randomized studies to delineate the role of these technologies in patients with mitral valve disease.
Topics: Bioprosthesis; Echocardiography, Doppler, Color; Echocardiography, Three-Dimensional; Echocardiography, Transesophageal; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Mitral Valve; Mitral Valve Insufficiency; Mitral Valve Stenosis; Prosthesis Design; Prosthesis Failure; Recovery of Function; Risk Factors; Tomography, X-Ray Computed; Transcatheter Aortic Valve Replacement; Treatment Outcome
PubMed: 29743999
DOI: 10.14797/mdcj-13-3-142 -
Revue Medicale de LiegeAfter aortic valve diseases, mitral valve diseases represent the most numerous indications of surgical or percutaneous valvular intervention. Surgical management is...
After aortic valve diseases, mitral valve diseases represent the most numerous indications of surgical or percutaneous valvular intervention. Surgical management is favoured in severe symptomatic mitral regurgitation. In case of high or prohibitive surgical risk, new techniques are developed to allow percutaneous, less invasive management. In these circumstances, MitraClip® allows the treatment of mitral regurgitation in case of adequate valve morphology. Percutaneous balloon valvuloplasty is currently the first-line treatment of mitral stenosis related to rheumatic disease when anatomical features are favourable. Alongside the Inoue technique, which remains the classical procedure, other approaches are available with encouraging results.
Topics: Aortic Valve; Catheterization; Humans; Mitral Valve; Mitral Valve Insufficiency; Mitral Valve Stenosis
PubMed: 31070320
DOI: No ID Found -
Anatolian Journal of Cardiology Jul 2022
Topics: Cardiac Surgical Procedures; Humans; Mitral Valve Stenosis; Tricuspid Valve
PubMed: 35791705
DOI: 10.5152/AnatolJCardiol.2022.7 -
The Journal of Thoracic and... Feb 2022For degenerative mitral disease, repair is superior to replacement; however, the best operative strategy for rheumatic mitral disease remains unclear. We evaluated the... (Comparative Study)
Comparative Study
OBJECTIVE
For degenerative mitral disease, repair is superior to replacement; however, the best operative strategy for rheumatic mitral disease remains unclear. We evaluated the association between decision-making in choosing repair versus replacement and outcomes across 2 decades of rheumatic mitral surgery.
METHODS
Patients undergoing isolated, first-time rheumatic mitral surgery were identified. Era 1 (1997-2008) and Era 2 (2009-2018) were distinguished by intraoperative assessment of anterior leaflet mobility/calcification (Era 2) in deciding between mitral repair versus replacement. Primary outcome was a composite of death, reoperation, and severe valve dysfunction.
RESULTS
Among 180 patients, age was 59 ± 14 years, and ejection fraction was 58% ± 10%. A higher proportion in Era 1 (n = 56) compared with Era 2 (n = 124) had preoperative atrial fibrillation (68% vs 46%; P = .006); the groups were otherwise similar. Primary indication was mitral stenosis in 69% (124 out of 180; pure = 35, mixed = 89) and did not differ by era (P = .67). During Era 1, 70% (39 out of 56) underwent repair, compared with 33% (41 out of 124) during Era 2 (P < .001). Freedom from death, reoperation, or severe valve dysfunction at 5 years was higher in Era 2 (72% ± 9%) than Era 1 (54% ± 13%; P = .04). Five-year survival was higher in Era 2 than Era 1, but did not differ between repair versus replacement. Five-year cumulative incidence of reoperation with death as a competing risk did not differ by era, but was higher after repair than replacement.
CONCLUSIONS
Careful assessment of anterior leaflet mobility/calcification to determine mitral repair or replacement was associated with improved outcomes. This decision-making strategy may alter the threshold for rheumatic mitral replacement in the current valve-in-valve era.
Topics: Adult; Aged; Aged, 80 and over; Female; Heart Valve Prosthesis Implantation; Hemodynamics; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Annuloplasty; Mitral Valve Insufficiency; Mitral Valve Stenosis; Postoperative Complications; Recovery of Function; Reoperation; Retrospective Studies; Rheumatic Heart Disease; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult
PubMed: 32620398
DOI: 10.1016/j.jtcvs.2020.04.118